ENGN Share Price Performance
US$1.53
-2.67 (-63.57%)
Price US$1.53
Share Pricen/a
enGene Therapeutics Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
ENGN Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
enGene Therapeutics Inc. Key Details
About ENGN
- Founded
- n/a
- Employees
- 82
- CEO
- WebsiteView website
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
